@article{3153137,
    title = "The Associations of Advanced Glycation End Products and Its Soluble
Receptor with Pancreatic Cancer Risk: A Case-Control Study within the
Prospective EPIC Cohort",
    author = "Grote, Verena A. and Nieters, Alexandra and Kaaks, Rudolf and and Tjonneland, Anne and Roswall, Nina and Overvad, Kim and Nielsen, Michael and R. Skjelbo and Clavel-Chapelon, Francoise and Boutron-Ruault, Marie and Christine and Racine, Antoine and Teucher, Birgit and Lukanova, and Annekatrin and Boeing, Heiner and Drogan, Dagmar and Trichopoulou, and Antonia and Trichopoulos, Dimitrios and Lagiou, Pagona and Palli, and Domenico and Sieri, Sabina and Tumino, Rosario and Vineis, Paolo and and Mattiello, Amalia and Argueelles Suarez, Marcial Vicente and Duell, Eric and J. and Sanchez, Maria-Jose and Dorronsoro, Miren and Huerta Castano, and Jose Maria and Barricarte, Aurelio and Jeurnink, Suzanne M. and Peeters, and Petra H. M. and Sund, Malin and Ye, Weimin and Regner, Sara and and Lindkvist, Bjorn and Khaw, Kay-Tee and Wareham, Nick and Allen, Naomi E. and and Crowe, Francesca L. and Fedirko, Veronika and Jenab, Mazda and and Romaguera, Dora and Siddiq, Afshan and Bueno-de-Mesquita, H. Bas and and Rohrmann, Sabine",
    journal = "Cancer Epidemiology, Biomarkers & Prevention",
    year = "2012",
    volume = "21",
    number = "4",
    pages = "619-628",
    publisher = "AMER ASSOC CANCER RESEARCH",
    issn = "1055-9965, 1538-7755",
    doi = "10.1158/1055-9965.EPI-11-1139",
    abstract = "Background: Advanced glycation end products (AGE) and their receptors
(RAGE) have been implicated in cancer development through their
proinflammatory capabilities. However, prospective data on their
association with cancer of specific sites, including pancreatic cancer,
are limited.
Methods: Prediagnostic blood levels of the AGE product
Ne-(carboxymethyl) lysine (CML) and the endogenous secreted receptor for
AGE (esRAGE) were measured using ELISA in 454 patients with exocrine
pancreatic cancer and individually matched controls within the European
Prospective Investigation into Cancer and Nutrition (EPIC). Pancreatic
cancer risk was estimated by calculating ORs with corresponding 95%
confidence intervals (CI).
Results: Elevated CML levels tended to be associated with a reduction in
pancreatic cancer risk [OR = 0.57 (95% CI, 0.32-1.01) comparing
highest with lowest quintile), whereas no association was observed for
esRAGE (OR = 0.98; 95% CI, 0.62-1.54). Adjustments for body mass index
and smoking attenuated the inverse associations of CML with pancreatic
cancer risk (OR = 0.78; 95% CI, 0.41-1.49). There was an inverse
association between esRAGE and risk of pancreatic cancer for cases that
were diagnosed within the first 2 years of follow-up [OR = 0.46 (95%
CI, 0.22-0.96) for a doubling in concentration], whereas there was no
association among those with a longer follow-up (OR = 1.11; 95% CI,
0.88-1.39; P-interaction = 0.002).
Conclusions and Impact: Our results do not provide evidence for an
association of higher CML or lower esRAGE levels with risk of pancreatic
cancer. The role of AGE/RAGE in pancreatic cancer would benefit from
further investigations. Cancer Epidemiol Biomarkers Prev; 21(4); 619-28.
(C) 2012 AACR."
}